Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)

OBJECTIVES: To assess the efficacy of inhaled ciclesonide in reducing the risk of adverse outcomes in COVID-19 outpatients at risk of developing severe illness. METHODS: COVERAGE is an open-label, randomized controlled trial. Outpatients with documented COVID-19, risk factors for aggravation, sympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Duvignaud, Alexandre, Lhomme, Edouard, Onaisi, Racha, Sitta, Rémi, Gelley, Ambre, Chastang, Julie, Piroth, Lionel, Binquet, Christine, Dupouy, Julie, Makinson, Alain, Lefèvre, Benjamin, Naccache, Jean-Marc, Roussillon, Caroline, Landman, Roland, Wallet, Cédrick, Karcher, Sophie, Journot, Valérie, Nguyen, Duc, Pistone, Thierry, Bouchet, Stéphane, Lafon, Marie-Edith, Molimard, Mathieu, Thiébaut, Rodolphe, de Lamballerie, Xavier, Joseph, Jean-Philippe, Richert, Laura, Saint-Lary, Olivier, Djabarouti, Sarah, Wittkop, Linda, Anglaret, Xavier, Malvy, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920965/
https://www.ncbi.nlm.nih.gov/pubmed/35304280
http://dx.doi.org/10.1016/j.cmi.2022.02.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920965/
https://www.ncbi.nlm.nih.gov/pubmed/35304280
http://dx.doi.org/10.1016/j.cmi.2022.02.031

Ejemplares similares